China NT Pharma Group Company Limited provided group earnings guidance for the six months ended 30 June 2020. The Board announced the Shareholders and potential investors that, based on the information currently available, the Board expects to record a significant increase in revenue by approximately 25% for the six months ended 30 June 2021 as compared to the revenue for the six months ended 30 June 2020; and the Board expects to record a significant decrease in net loss by approximately 80% for the six months ended 30 June 2021 as compared to the net loss for the six months ended 30 June 2020.